Nonmuscle myosin ii inhibitors

Inventors: Courtney Anne Miller (Jupiter, FL); Patrick Robert Griffin (Jupiter, FL); Theodore Mark Kamenecka (Palm Beach Gardens, FL); Gavin Rumbaugh (Jupiter, FL); Matthew Surman (Albany, NY); Steve Young (Lansdale, PA); Steven Duddy (Ann Arbor, MI); Laszlo Radnai (East Palm Beach Gardens, FL)

Assignee: THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.

C07D471/04 C07D471/14 C07D495/14 C07D519/00

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,338,240
App. No.: 18/169,660
Granted: Jun 24, 2025
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis /marijuana, nicotine, and activities including gambling. Compounds are of general formula with substituents as defined herein.

Claims (20)

1. A compound of formula (IIa) or (IIb)

wherein

X is a group of formula

wherein wavy lines indicate points of bonding;

R 1 is independently at each occurrence H, (C1-C4)alkyl, CF 3 , nitro, or halo;

Ar is a monocyclic aryl, a monocyclic heteroaryl, or a bicyclic heteroaryl substituted with 1, 2 or 3 R 2 , or a bicyclic aryl substituted with 0, 1, 2 or 3 R 2 ; wherein

when Ar is a monocyclic aryl, then R 2 is independently at each occurrence hydroxymethyl, R 2 NCH 2 wherein R is H or alkyl, or nitro; and

when Ar is a bicyclic aryl or heteroaryl or a monocyclic heteroaryl, then R 2 is independently at each occurrence (C1-C4)alkyl, (C1-C4)alkoxyl), (C1-C4)alkoxycarbonyl, (C1-C4)haloalkyl, hydroxymethyl, R 2 NCH 2 wherein R is H or alkyl, cyano, nitro, halo, or CF 3 ;

R 3 is independently at each occurrence H or CH 3 ;

provided that the compound is not any of the formulae

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein at least one R 1 group of formula (IIa) or (IIb) is methyl, halo or CF 3 .

3. The compound of claim 1 wherein Ar is a group of formula

wherein a wavy line indicates a point of bonding.

4. The compound of claim 1 wherein Ar is a pyrazolyl, thiophenyl, isoquinolinyl, benzoxazolyl, quinazolinyl, isoxazolyl, cinnolinyl, quinoxalinyl, benzisoxazolyl, benzothiadiazolyl, pyrazolopyridinyl, imidazopyridinyl, thieopyridinyl, dihydrobenzoxazinyl, triazolopyridinyl, dihydropyridoxazinyl, tetrahydrobenzoxazepinyl, dihydrobenzodioxinyl, dihydrobenzothiazinyl, tetrahydroquinolinyl, tetrahydronaphthyl, or chromanyl ring system, any of which is substituted with 1, 2, or 3 R 2 .

5. A compound or pharmaceutically acceptable salt thereof, of any one of the formulae:

BPN-0027181

BPN-0028898

BPN-0028863

BPN-0027216

Assignments (5)